Vizsgálati helyszín
Highlands Oncology Group, PA
Springdale, Arkansas 72762, Egyesült ÁllamokMég nincs intézményhez kötve
- 13futó vizsgálat
- 1lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 14 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis5 vizsgálat
- 1. fázis3 vizsgálat
- 1/2. fázis3 vizsgálat
- 2. fázis3 vizsgálat
- Állapot
- Toboroz8 vizsgálat
- Fut, nem toboroz5 vizsgálat
- Lezárult1 vizsgálat
- Fő szponzor
- Pfizer10 vizsgálat
- Seagen, a wholly owned subsidiary of Pfizer1 vizsgálat
- Shanghai Henlius Biotech1 vizsgálat
- Stemline Therapeutics, Inc.1 vizsgálat
- University of Arkansas1 vizsgálat
Futó vizsgálatok
Toboroz
A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
NCT07477587· 1. fázis· Shanghai Henlius Biotech· Forrás
Contact: Yinping Zhong
Toboroz
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
NCT07421700· 1/2. fázis· Pfizer· Forrás
Toboroz
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
NCT07227415· 1/2. fázis· Pfizer· Forrás
Toboroz
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
NCT07227298· 1/2. fázis· Pfizer· Forrás
Toboroz
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT07144280· 3. fázis· Pfizer· Forrás
Toboroz
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
NCT07028853· 3. fázis· Pfizer· Forrás
Toboroz
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT06760637· 3. fázis· Pfizer· Forrás
Toboroz
Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence
NCT05952934· 2. fázis· University of Arkansas· Forrás
Contact: Jennifer Worth
Fut, nem toboroz
ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study
NCT05596409· 2. fázis· Stemline Therapeutics, Inc.· Forrás
Fut, nem toboroz
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
NCT05538130· 1. fázis· Pfizer· Forrás
Fut, nem toboroz
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
NCT05355701· 1. fázis· Pfizer· Forrás
Fut, nem toboroz
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
NCT05059522· 3. fázis· Pfizer· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek